Allocation of series Y ordinary bearer shares of the Company

Current report no. 11/2026

Date of preparation: 12 March 2026

Subject: Allocation of series Y ordinary bearer shares of the Company

Legal basis: Article 17(1) MAR – inside information

The Management Board of Captor Therapeutics S.A. with its registered office in Wrocław (the ‘Company’), with reference to: current report No. 7/2026 of 2 March 2026, current report No. 9/2026 of 2 March 2026 and current report No. 10/2026 of 2 March 2026, hereby announces that on 12 March 2026 the Company's Management Board adopted a resolution to allocate 800,000 ordinary bearer shares of series Y of the Company with a nominal value of PLN 0.10 each and a total nominal value of PLN 80,000.00 ‘Series Y Shares’. At the same time, the Company announces that, as of today, agreements have been concluded with investors to subscribe for Series Y Shares, and the required cash contributions have been made in full by all subscribers of Series Y Shares.

ADDITIONAL INFORMATION

This current report has been prepared solely for the purpose of fulfilling the obligations under Article 17(1) of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse and repealing Directive 2003/ 6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC MAR, as the Company considered the above information to meet the criteria for confidential information within the meaning of Article 7 MAR. This report does not serve in any way, directly or indirectly, to promote the offer, subscription or purchase of Series Y Shares and does not constitute advertising or promotional material prepared or published by the Company for the purpose of promoting the offer of Series Y Shares or to encourage investors, directly or indirectly, to purchase or subscribe for Series Y Shares.